KRAS and neoplasm: KRAS G12C mutations occur in 3% to 4% of mCRC patients, driving the tumor’s growth by suppressing the hydrolysis of GTP, which causes KRAS to transition to an active GTP-binding state and activate pro-tumorigenic effector signaling [60].